March 7, 2024 News by Margarida Maia, PhD ACTRIMS 2024: MRI Paramagnetic rim lesions tied to cognitive decline The presence of paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, may help identify people with multiple sclerosis (MS) who are more likely to have cognitive decline…
March 7, 2024 News by Margarida Maia, PhD ACTRIMS 2024: An antihistamine may speed MS disease progression The antihistamine clemastine accelerated disease progression by more than five times in some adults with progressive multiple sclerosis (MS) who received it in a Phase 1/2 trial, new data show. Joanna Kocot, PhD, a neuroscientist at the National…
March 6, 2024 News by Marisa Wexler, MS ACTRIMS 2024: 2 treatments to aid remyelination near clinical trials Convelo Therapeutics is developing two experimental oral treatments to promote myelin repair in multiple sclerosis (MS) and both have shown promise in preclinical models. The company is in the final stages of safety studies in large animals.
March 6, 2024 News by Margarida Maia, PhD ACTRIMS 2024: Tolebrutinib fails to eliminate iron rim lesions in Phase 2 trial Nearly one year of treatment with tolebrutinib, an oral small molecule being developed by Sanofi, failed to eliminate iron rim lesions in adults with multiple sclerosis (MS), according to data from a small Phase 2…
March 5, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Evobrutinib fails to show superiority to Aubagio in Phase 3 trials The experimental BTK inhibitor evobrutinib was no better than Aubagio (teriflunomide) at preventing relapses, reducing brain lesions, or slowing disability progression in people with relapsing forms of multiple sclerosis (MS), according to data from two Phase…
March 5, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Progressive MS patients show gains in NG-01 OLE Repeated treatment with the mesenchymal stem cell therapy NG-01 led to gains in mobility and cognition, along with patient-reported quality of life, for most people with progressive multiple sclerosis (MS) in an extension study. Markers of nerve…
March 4, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Vidofludimus calcium lowers NfL levels in progressive MS Treatment with Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium (IMU-838) lowered the levels of a nerve damage marker in people with all subtypes of progressive multiple sclerosis (MS), including those without recent inflammatory activity. That’s according…
March 4, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Most patients relapse-free after 6 years on Zeposia About two-thirds of people with relapsing forms of multiple sclerosis (MS) remained completely free from relapses over six years of treatment with Zeposia (ozanimod) in the DAYBREAK clinical trial. Most also saw no sustained disability progression during…
March 1, 2024 News by Marisa Wexler, MS ACTRIMS 2024: Molecule made by gut bacteria seen to ease MS in mice Supplements of indole 3-lactate (ILA), a molecule made by gut bacteria, significantly reduced disease severity and promoted myelin repair in mouse models of multiple sclerosis (MS). That’s according to new findings presented by Larissa Jank, PhD, a postdoctoral…